Boehringer Ingelheim and DCRI Expand Collaboration

Article

Boehringer Ingelheim and the Duke Clinical Research Institute (DCRI) announce the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry.

Boehringer Ingelheim and the Duke Clinical Research Institute (DCRI) announce the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry. The expansion of this registry, designed to uncover insights into the rare disease, will vastly increase the study’s enrollment.

Read the full release here

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.